

July 23, 2018  
Stem Cell & Device Laboratory Co., Ltd.  
<http://scad-kyoto.com/>

## **SCAD Inc.'s technologies introduced at the 45<sup>th</sup> Annual Meeting of the Japanese Society of Toxicology**

Stem Cell & Device Laboratory, Inc. (SCAD)'s collaborator Associate Professor Ikuro Suzuki from Tohoku Institute of Technology introduced the use of SCAD's nanofiber scaffold technologies for neurotoxicity evaluation at the 45<sup>th</sup> Annual Meeting of the Japanese Society of Toxicology in Osaka, Japan (details below).

Conference name	45 <sup>th</sup> Annual Meeting of the Japanese Society of Toxicology ( <a href="http://jsot2018.jp/index.html">http://jsot2018.jp/index.html</a> )
Time and Place	July 18, 2018 (12:15-13:15) Luncheon Seminar 2 (Host: Veritas Corporation)
Venue	Osaka International Convention Center
Title	Development of a toxicity evaluation method based on the functional properties of human iPS cell-derived neurons as indicators
Presenter	Associate Professor Ikuro Suzuki (Tohoku Institute of Technology)

This luncheon seminar introduced the use of SCAD-MT<sup>TM</sup> neuron for toxicity evaluation based on the measurement of the electrical activity of human iPS cell-based neural networks, including synchronized burst firing and the propagation of the electrical activity (Suzuki Lab).

This presentation showed that SCAD-MT<sup>TM</sup> neuron overcomes the major obstacles hindering the measurement of neuronal activity with multi-electrode array (MEA) systems. It was also shown that SCAD-MT<sup>TM</sup> neuron can detect earlier the electrical activity in the neural networks by increasing synapse formation enabled by the directional control of fiber-based culturing technologies (patent pending). In addition, Assoc. Prof. Suzuki's lab and SCAD are working on the development of a new method of neural activity measurement using SCAD-MT<sup>TM</sup> neuron.

We strive towards the realization of "a new society created by stem cells" through the establishment of collaborations with key partners fostering the commercialization of neuron devices with the highest quality and functionality.

### **About SCAD**

SCAD is an innovative biotech company offering cell product and service innovations that accelerate drug discovery and development through the convergence of nanotechnology, micro-engineering, and stem cell technologies. By harnessing the leading-edge technologies of Prof. Norio Nakatsuji's group at

Kyoto University, SCAD is committed to the development, manufacturing and commercialization of the next generation of cells and cell devices based on iPS cell technologies. SCAD's proprietary technologies in nanofiber-based cell culturing allow the creation of 3D, multilayered microtissues that closely recapitulate native tissues through increasing levels of maturity and functionality. Our initial offering is centered on the SCAD-MT™ cardiomyocyte, a myocardial microtissue, but other types of tissues are expected to come to market soon. As a company, we strive to contribute to the wellbeing of society by enabling the faster delivery of efficacious and safe medicines to patients.

**For more information**

Stem Cell & Device Laboratory, Inc. (SCAD)

Management Section: Mrs. Sonoko Chiaki

TEL: 075-744-1114; E-mail: [scad.info@scad-kyoto.com](mailto:scad.info@scad-kyoto.com)